Upgrades by analysts, especially to an Overweight rating, indicate a positive outlook on the stock, suggesting potential outperformance in the market. The new price target of $9 further emphasizes the analyst's bullish stance on GoodRx Holdings, likely leading to increased investor interest and potentially driving the stock price up in the short term.